Jiangsu Kanion Pharmaceutical Co Ltd. Stock Analysis 600557.SS

Jiangsu Kanion Pharmaceutical Co., Ltd. engages in the manufacturing & sales of proprietary Chinese medicine preparations and health products. The company is headquartered in Lianyungang, Jiangsu and currently employs 5,379 full-time employees. The company went IPO on 2002-09-18. The firm's respiratory and infectious disease product line includes Jin Zhen oral liquid, Re Du Ning injection and others. The firm's cardiovascular and cerebrovascular product line includes Ginkgo biloba diterpenoid lactone glucosamine injection, Tianshu capsules and others. The firm's gynecological product line includes Guizhi Fuling Capsules, Sanjie Analgesic Capsules and others. The firm's orthopedics and traumatology product line includes compound Nanxing pain relieving cream, Yaobitong capsule, Jingu pain relieving gel and others. The firm is also engaged in the research and development of chemical drugs and biological drugs. The firm mainly conducts its business in the domestic market.